Assessment of an In Silico Mechanistic Model for Proarrhythmia Risk Prediction Under the CiPA Initiative

Apr 30, 2018 • By Zhihua Li, Bradley J. Ridder, Xiaomei Han, Wendy W. Wu, Jiansong Sheng, Phu N. Tran, Min Wu, Aaron Randolph, Ross H. Johnstone, Gary R. Mirams, Yuri Kuryshev, James Kramer, Caiyun Wu, William J. Crumb Jr. and David G. Strauss

The International Council on Harmonization (ICH) S7B and E14 regulatory guidelines are sensitive but not specific for predicting which drugs are pro-arrhythmic. In response, the Comprehensive In Vitro Proarrhythmia Assay (CiPA) was proposed that integrates multi-ion channel pharmacology data in…

Read more

Quinidine Interactions With Human Atrial Potassium Channels

Apr 24, 2018 • By Neviana I. Nenov, William J. Crumb, Jr, John D. Pigott, Lynn H. Harrison, Jr, Craig W. Clarkson

Abstract Clinical studies have suggested that quinidine is less effective when used for the treatment of atrial arrhythmias in pediatric patients compared with its clinical effectiveness in the adult patient population. Age-related changes in the cardiac actions of quinidine on action potential…

Read more

Comprehensive Translational Assessment of Human- Induced Pluripotent Stem Cell Derived Cardiomyocytes for Evaluating Drug-Induced Arrhythmias

Oct 03, 2016 • By Ksenia Blinova, Jayna Stohlman, Jose Vicente, Dulciana Chan, Lars Johannesen, Maria P. Hortigon-Vinagre, Victor Zamora, Godfrey Smith, William J. Crumb, Li Pang, Beverly Lyn-Cook, James Ross, Mathew Brock, Stacie Chvatal, Daniel Millard, Loriano Galeotti, Norman Stockbridge, and David G. Strauss

Abstract Induced pluripotent stem cell-derived cardiomyocytes (iPSC-CM) hold promise for assessment of drug-induced arrhythmias and are being considered for use under the comprehensive in vitro proarrhythmia assay (CiPA). We studied the effects of 26 drugs and 3 drug combinations on 2 commercially…

Read more

An evaluation of 30 clinical drugs against the comprehensive in vitro proarrhythmia assay (CiPA) proposed ion channel panel

Mar 30, 2016 • By William J. Crumb Jr. , Jose Vicente, Lars Johannesen, David G. Strauss

Abstract Introduction: The Comprehensive in vitro Proarrhythmia Assay (CiPA) is intended to address the misidentification of drug-associated torsade de pointes risk based solely on hERG and QT data. This newparadigmwill consist of four interrelated components, one of which is a panel consisting of…

Read more

Request a Quote